Cowen & Co. Believes Array Biopharma (NASDAQ: ARRY) Won’t Stop Here

By Carrie Williams

In a report released today, Chris Shibutani from Cowen & Co. maintained a Buy rating on Array Biopharma (ARRYResearch Report), with a price target of $25. The company’s shares opened today at $47.04, close to its 52-week high of $47.05.

According to, Shibutani is a 3-star analyst with an average return of 2.0% and a 41.1% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Array Biopharma with a $36.71 average price target, implying a -22.0% downside from current levels. In a report issued on June 4, Piper Jaffray also maintained a Buy rating on the stock with a $37 price target.

See today’s analyst top recommended stocks >>

Based on Array Biopharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $37.49 million. In comparison, last year the company had a GAAP net loss of $22.85 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Array BioPharma, Inc. engages in the research, development, and commercialization of targeted small molecule drugs for the treatment of cancer and other high-burden diseases. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO.